Matrix Metalloproteinases Neutralizing Agents in Oral Lichen Planus

Early Phase 1UnknownNCT04336488

Jaylane kadry Ghonima40 enrolled

Overview

The current study will be conducted to evaluate the effectiveness of matrix metalloproteinases inhibitors on erosive oral lichen planus.

Matrix metalloproteinases inhibitor (Orochem) will be given to patients with Oral erosive lichen planus three times daily for 3 weeks. Then the subjective discomfort and pain severity as well as the objective disease severity scores will be collected.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

Conditions

Oral Lichen Planus

Interventions

Matrix Metalloproteinase Inhibitors (Orochem)DRUG

topical application of MMP inhibitors for 3 weeks to evaluate its effectiveness in treating oral lichen planus

Kenacort A,DRUG

topical application of both drugs 3 times daily for 3 weeks as an active control

Eligibility

Sex: ALLMin age: 25 Years

Medical Language ↔ Plain English

Inclusion Criteria: * patients diagnosed with erosive OLP confirmed with a biopsy. * patients should have symptomatic lesions Exclusion Criteria: * Patients who were under anticoagulant medications, suffering from any systemic diseases or having any physical or mental abnormality, pregnant and lactating women, smokers.

Locations (1)

periodontology department, Faculty of dentistry, Alexandria University

Alexandria, Egypt

Outcomes

Primary Outcomes

change in disease severity score

Thongprasom disease severity score (5-0)

Time frame: change in disease severity score from baseline to 3 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.